The global biobanking market size is expected to reach around US$ 115.4 billion by 2030 from US$ 69 billion in 2021 and is expected to grow at an impressive double-digit rate of 5.9% from 2022 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global biobanking market for the period 2017-2030, wherein 2022 to 2030 is the forecast period and 2021 is considered as the base year.
Report Highlights
- Based on the product, the equipment segment accounted for a revenue share of over 75% and dominated the global biobanking market in 2021. The high costs associated with the acquisition of the biobanking equipment have resulted in the higher revenue generation. Furthermore, the rise in the number of biobanks across the globe in the recent times has fostered the growth of this segment.
- On the basis of service, lab processing is anticipated to be the most opportunistic segment. This is mainly due to the increased investments in the clinical research and clinical trials on COVID-19 infection and the higher engagement of various pharma companies in the development of drugs and vaccines against the COVID-19 disease.
- Based on the specimen, the human tissues were the leading segment and are expected to be the fastest-growing segment as well. The higher availability of the human tissues owing to the higher demand for it has fueled the growth of this segment.
- Depending on the biobank type, the virtual biobank segment is projected to witness the highest growth rate during the forecast period. The rising adoption of the software, digital technology, and automation technologies in the biobanking industry has led to the rapid emergence of the virtual biobank segment.
- By application, the drug discovery & clinical research segment dominated the global biobanking market in 2021 with revenue share of 38%. This is attributed to the increased demand for the biosamples in the clinical studies and drug discovery activities. The recent outbreak of the COIVID-19 has fueled the number of clinical studies and research in 2020.
Our Free Sample Reports Includes:
- In-depth Industry Analysis, Introduction, Overview, and COVID-19 Pandemic Outbreak.
- Impact Analysis 180+ Pages Research Report (Including latest research).
- Provide chapter-wise guidance on request 2022 Updated Regional Analysis with Graphical Representation of Trends, Size, & Share, Includes Updated List of figures and tables.
- Updated Report Includes Major Market Players with their Sales Volume, Business Strategy and Revenue Analysis by using Precedence Research methodology.
Download Free Sample Copy Here (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1641
Market Dynamics
Driver
Rising trend of conserving cord blood stem cells of newborns
Cord blood is derived from the umbilical cord after the delivery of the baby and it is an abundant source of cord blood stem cells, which is highly used for clinical research. The demand for this cord blood stem cell is high in the field of biobanking. In 2020, Lund University launched the globe’s largest stem cell biobanking in Sweden with an intention to help the researchers to conduct studies on the diseases like Parkinson’s and Alzheimer’s. Therefore, the rising demand for the cord blood stem cell for the clinical research is expected to drive the market growth during the forecast period.
Restraint
High costs associated with automation
With the rise in the digital technologies, the virtual biobanks and the other digital technologies paved its way in the biobanking industry. The biospecimen storage tools are well-equipped with the advanced functionalities and hence the costs of acquiring it is higher. The high costs associated with the automation technologies in the biobanking industry presents a challenge for the market players to achieve sustainability.
Opportunities
Integration of software led to the rise of virtual biobanking
The introduction of software in the biobanking industry has given rise to the virtual biobanking. The virtual technologies are facilitating the researchers to smoothly conduct their studies and reduce the time limitations. The rising investments in the development of software technologies are expected to offer lucrative growth opportunities to the market players in the virtual biobanking market in the foreseeable future.
Challenge
Sustainability in long term
Achieving sustainability in the long term is a major challenge for the market players. There is an insecurity related to the long term funding in the biobanking. To achieve sustainability a balance between the social, financial, and operational dimension is required. Therefore, sustainability is a need for remaining operative and effective in the long term in the global biobanking market.
Recent Developments
- In April 2020, Fonds de recherche du Quebecand Genome Quebec together started Quebec COVID-19 biobank in Canada.
- In March 2021, UK Biobank added new data sets to their databaseabout measuring of the range of circulation metabolomics biomarkers.
Research Methodology
A unique research methodology has been utilized to conduct comprehensive research on the growth of the global biobanking market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the draw conclusions. Secondary sources referred to by analysts during the production of the global market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of our study on the market as a primary source.
These primary and secondary sources provided exclusive information during interviews, which serves as a validation from mattress topper industry leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global biobanking market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped to estimates the future prospects of the global market more reliable and accurate.
Why should you invest in this report?
If you are aiming to enter the global biobanking market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for biobanking are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2022-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global biobanking market include:
- Thermo Fisher Scientific Inc.
- Tecan Trading AG
- QIAGEN
- Hamilton Company
- Brooks Life Sciences
- TTP Labtech
- VWR International, LLC.
- Promega Corporation
- Worthington Industries
- BD
- Merck KGaA
- Biokryo GmbH
- Cell&Co BioServices
- RUCDR Infinite Biologics
- Modul-Bio
Market Segmentation:
By Product
- Equipment
- Consumables
- Laboratory Information Systems
By Service
- Biobanking and Repository
- Validation/Qualification
- Lab Processing
- Cold Chain Logistic
- Others
By Biospecimen Type
- Human Tissues
- Stem Cells
- Organs
- Others
By Biobank
- Physical Biobanks
- Virtual Biobanks
By Application
- Drug Discovery and Clinical Research
- Therapeutics
- Clinical Diagnostics
- Others
By Type of Biobank
- Population-based Biobanks
- Disease-oriented Biobanks
By Ownership
- National/regional agency
- Non-Profit Organization
- Universities
- Private Organization
By Storage
- Manual Storage
- Automated Storage
Regional Analysis:
The geographical analysis of the global biobanking market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global biobanking Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global biobanking market in 2030?
- What is the expected CAGR for the biobanking market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global biobanking market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Biobanking Market, By Service
7.1. Biobanking Market, by Service, 2021-2030
7.1.1. Biobanking and Repository
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Validation/Qualification
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Lab Processing
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Cold Chain Logistic
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. Other
7.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Biobanking Market, By Product
8.1. Biobanking Market, by Product, 2021-2030
8.1.1. Equipment
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Consumables
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Laboratory Information Systems
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Biobanking Market, By Biospecimen
9.1. Biobanking Market, by Biospecimen, 2021-2030
9.1.1. Human Tissues
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Stem Cells
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Organs
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Biobanking Market, By Biobank
10.1. Biobanking Market, by Biobank, 2021-2030
10.1.1. Physical Biobanks
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Virtual Biobanks
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Biobanking Market, By End-use
11.1. Biobanking Market, by End-use, 2021-2030
11.1.1. Drug Discovery and Clinical Research
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Therapeutics
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Clinical Diagnostics
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Biobanking Market, By Type of Biobank
12.1. Biobanking Market, by Type of Biobank, 2021-2030
12.1.1. Population-based Biobanks
12.1.1.1. Market Revenue and Forecast (2017-2030)
12.1.2. Disease-oriented Biobanks
12.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 13. Global Biobanking Market, By Ownership
13.1. Biobanking Market, by Ownership, 2021-2030
13.1.1. National/regional agency
13.1.1.1. Market Revenue and Forecast (2017-2030)
13.1.2. Non-Profit Organization
13.1.2.1. Market Revenue and Forecast (2017-2030)
13.1.3. Universities
13.1.3.1. Market Revenue and Forecast (2017-2030)
13.1.4. Private Organization
13.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 14. Global Biobanking Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Service (2017-2030)
14.1.2. Market Revenue and Forecast, by Product (2017-2030)
14.1.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.1.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.1.5. Market Revenue and Forecast, by End-use (2017-2030)
14.1.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.1.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.1.8. U.S.
14.1.8.1. Market Revenue and Forecast, by Service (2017-2030)
14.1.8.2. Market Revenue and Forecast, by Product (2017-2030)
14.1.8.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.1.8.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.1.8.5. Market Revenue and Forecast, by End-use (2017-2030)
14.1.8.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.1.8.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Service (2017-2030)
14.1.9.2. Market Revenue and Forecast, by Product (2017-2030)
14.1.9.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.1.9.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.1.9.5. Market Revenue and Forecast, by End-use (2017-2030)
14.1.9.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.1.9.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.2. Europe
14.2.1. Market Revenue and Forecast, by Service (2017-2030)
14.2.2. Market Revenue and Forecast, by Product (2017-2030)
14.2.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.2.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.2.5. Market Revenue and Forecast, by End-use (2017-2030)
14.2.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.2.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Service (2017-2030)
14.2.8.2. Market Revenue and Forecast, by Product (2017-2030)
14.2.8.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.2.8.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.2.8.5. Market Revenue and Forecast, by End-use (2017-2030)
14.2.8.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.2.8.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.2.9. Germany
14.2.9.1. Market Revenue and Forecast, by Service (2017-2030)
14.2.9.2. Market Revenue and Forecast, by Product (2017-2030)
14.2.9.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.2.9.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.2.9.5. Market Revenue and Forecast, by End-use (2017-2030)
14.2.9.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.2.9.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.2.10. France
14.2.10.1. Market Revenue and Forecast, by Service (2017-2030)
14.2.10.2. Market Revenue and Forecast, by Product (2017-2030)
14.2.10.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.2.10.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.2.10.5. Market Revenue and Forecast, by End-use (2017-2030)
14.2.10.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.2.10.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.2.11. Rest of Europe
14.2.11.1. Market Revenue and Forecast, by Service (2017-2030)
14.2.11.2. Market Revenue and Forecast, by Product (2017-2030)
14.2.11.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.2.11.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.2.11.5. Market Revenue and Forecast, by End-use (2017-2030)
14.2.11.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.2.11.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Service (2017-2030)
14.3.2. Market Revenue and Forecast, by Product (2017-2030)
14.3.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.3.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.3.5. Market Revenue and Forecast, by End-use (2017-2030)
14.3.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.3.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.3.8. India
14.3.8.1. Market Revenue and Forecast, by Service (2017-2030)
14.3.8.2. Market Revenue and Forecast, by Product (2017-2030)
14.3.8.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.3.8.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.3.8.5. Market Revenue and Forecast, by End-use (2017-2030)
14.3.8.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.3.8.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.3.9. China
14.3.9.1. Market Revenue and Forecast, by Service (2017-2030)
14.3.9.2. Market Revenue and Forecast, by Product (2017-2030)
14.3.9.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.3.9.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.3.9.5. Market Revenue and Forecast, by End-use (2017-2030)
14.3.9.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.3.9.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.3.10. Japan
14.3.10.1. Market Revenue and Forecast, by Service (2017-2030)
14.3.10.2. Market Revenue and Forecast, by Product (2017-2030)
14.3.10.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.3.10.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.3.10.5. Market Revenue and Forecast, by End-use (2017-2030)
14.3.10.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.3.10.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.3.11. Rest of APAC
14.3.11.1. Market Revenue and Forecast, by Service (2017-2030)
14.3.11.2. Market Revenue and Forecast, by Product (2017-2030)
14.3.11.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.3.11.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.3.11.5. Market Revenue and Forecast, by End-use (2017-2030)
14.3.11.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.3.11.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Service (2017-2030)
14.4.2. Market Revenue and Forecast, by Product (2017-2030)
14.4.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.4.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.4.5. Market Revenue and Forecast, by End-use (2017-2030)
14.4.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.4.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.4.8. GCC
14.4.8.1. Market Revenue and Forecast, by Service (2017-2030)
14.4.8.2. Market Revenue and Forecast, by Product (2017-2030)
14.4.8.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.4.8.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.4.8.5. Market Revenue and Forecast, by End-use (2017-2030)
14.4.8.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.4.8.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.4.9. North Africa
14.4.9.1. Market Revenue and Forecast, by Service (2017-2030)
14.4.9.2. Market Revenue and Forecast, by Product (2017-2030)
14.4.9.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.4.9.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.4.9.5. Market Revenue and Forecast, by End-use (2017-2030)
14.4.9.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.4.9.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.4.10. South Africa
14.4.10.1. Market Revenue and Forecast, by Service (2017-2030)
14.4.10.2. Market Revenue and Forecast, by Product (2017-2030)
14.4.10.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.4.10.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.4.10.5. Market Revenue and Forecast, by End-use (2017-2030)
14.4.10.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.4.10.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.4.11. Rest of MEA
14.4.11.1. Market Revenue and Forecast, by Service (2017-2030)
14.4.11.2. Market Revenue and Forecast, by Product (2017-2030)
14.4.11.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.4.11.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.4.11.5. Market Revenue and Forecast, by End-use (2017-2030)
14.4.11.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.4.11.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Service (2017-2030)
14.5.2. Market Revenue and Forecast, by Product (2017-2030)
14.5.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.5.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.5.5. Market Revenue and Forecast, by End-use (2017-2030)
14.5.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.5.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.5.8. Brazil
14.5.8.1. Market Revenue and Forecast, by Service (2017-2030)
14.5.8.2. Market Revenue and Forecast, by Product (2017-2030)
14.5.8.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.5.8.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.5.8.5. Market Revenue and Forecast, by End-use (2017-2030)
14.5.8.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.5.8.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Service (2017-2030)
14.5.9.2. Market Revenue and Forecast, by Product (2017-2030)
14.5.9.3. Market Revenue and Forecast, by Biospecimen (2017-2030)
14.5.9.4. Market Revenue and Forecast, by Biobank (2017-2030)
14.5.9.5. Market Revenue and Forecast, by End-use (2017-2030)
14.5.9.6. Market Revenue and Forecast, by Ownership (2017-2030)
14.5.9.7. Market Revenue and Forecast, by Type of Biobank (2017-2030)
Chapter 15. Company Profiles
15.1. Thermo Fisher Scientific Inc.
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Tecan Trading AG
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. QIAGEN
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Hamilton Company
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Brooks Life Sciences
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. TTP Labtech
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. VWR International, LLC.
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Promega Corporation
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Worthington Industries
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. BD
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
15.11. Merck KGaA
15.11.1. Company Overview
15.11.2. Product Offerings
15.11.3. Financial Performance
15.11.4. Recent Initiatives
15.12. Biokryo GmbH
15.12.1. Company Overview
15.12.2. Product Offerings
15.12.3. Financial Performance
15.12.4. Recent Initiatives
15.13. Cell&Co BioServices
15.13.1. Company Overview
15.13.2. Product Offerings
15.13.3. Financial Performance
15.13.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1641
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
0 Comments